|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:ivacaftor
gptkb:tezacaftor
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
R07AX30
|
|
gptkbp:developedBy
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:tezacaftor/ivacaftor
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Symdeko
|
|
gptkbp:indication
|
treatment of cystic fibrosis in patients with specific CFTR mutations
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
CFTR modulator
potentiator and corrector of CFTR protein
|
|
gptkbp:pregnancyCategory
|
N
|
|
gptkbp:prescribes
|
patients aged 6 years and older with cystic fibrosis with at least one F508del mutation in the CFTR gene
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
sinus congestion
increased liver enzymes
|
|
gptkbp:usedFor
|
cystic fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|